BioMarin strikes deal with Elliott, agrees to review business
BioPharma
Source: biopharmadive.com
📰 Mark Enyedy News
Mark Enyedy News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Enyedy. Real-time updates on events, politics, business and more.
BioMarin Announces Governance Enhancements and Value Creation Initiatives
/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), a global biotechnology company dedicated to transforming lives through genetic discovery, today...
United States Indiana University Northeastern University Alexander Hardy Iovance Biotherapeutics Traci Mccarty
Source: prnewswire.com
BioMarin settles with Elliott, adds 3 independent directors
BioMarin reached a settlement with activist investor Elliott Investment Management where the biotechnology company will add three independent directors to its board and form a committee to...
Source: marketscreener.com
BioMarin Announces Governance Enhancements and Value Creation Initiatives
BioMarin Pharmaceutical Inc. , a global biotechnology company dedicated to transforming lives through genetic discovery, today announced several initiatives to enhance corporate governance and long-term shareholder...
United States Northeastern University Indiana University Marni Kottle Daiichi Sankyo Iovance Biotherapeutics
Source: lelezard.com
AbbVie agrees to acquire ImmunoGen for around $10.1bn
AbbVie has signed a definitive agreement to acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx) in a deal that is expected to speed up the former’s commercial and clinical presence in the solid tumour segment.
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
Proposed acquisition will accelerate AbbVies entry into the commercial market for ovarian cancer ELAHERE® is a first-in-class antibody-drug conjugate (ADC)...
Source: prnewswire.com
AbbVie buys ImmunoGen for $10.1 billion, expanding cancer drug portfolio
AbbVie is acquiring rival biotech firm ImmunoGen for $10.1 billion, giving it access to ImmunoGen's flagship ovarian cancer treatment Elahere, which was granted accelerated approval from the FDA last year.
Source: biopharma-reporter.com
Abbvie to Acquire ImmunoGen for $10.1 Billion
ImmunoGen's oncology portfolio has the potential to help drive long-term revenue growth for AbbVie's oncology franchise.
Richarda Gonzalez Mark Enyedy Abbvie Inc European Union Marketing Authorization Application Biologic License Application
Source: powderbulksolids.com
AbbVie strikes deal to acquire Waltham's ImmunoGen for more than $10 billion
It’s the largest acquisition of a Massachusetts company this year.
United States Daiichi Sankyo Richard Gonzalez Mark Enyedy York Stock Exchange New York Stock Exchange
Source: bostonglobe.com
AbbVie to acquire ADC manufacturer ImmunoGen for $10.1B in oncology play
The ImmunoGen deal, which is expected to close in the middle of 2024, is also estimated to be accretive to AbbVie’s diluted earnings per share beginning in 2027.
Richarda Gonzalez Eli Lilly Mablink Bioscience Kristen Harrington Smith Mark Enyedy Drug Administration
Source: mmm-online.com